Arena Pharmaceuticals (ARNA) Shares are Up 12.16%

Arena Pharmaceuticals (ARNA) : Traders are bullish on Arena Pharmaceuticals (ARNA) as it has outperformed the S&P 500 by a wide margin of 4.59% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 11.57%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 12.16% in the last 1 week, and is up 2.47% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 4.34% and the 50-Day Moving Average is 1.09%.The 200 Day SMA reached 2.99% Arena Pharmaceuticals, Inc. has dropped 9.78% during the last 3-month period . Year-to-Date the stock performance stands at -12.63%.


Arena Pharmaceuticals (ARNA) : The most positive equity analysts on Arena Pharmaceuticals (ARNA) expects the shares to touch $6, whereas, the least positive believes that the stock will trade at $4 in the short term. The company is covered by 3 Wall Street Brokerage Firms. The average price target for shares are $4.5 with an expected fluctuation of $1.32 from the mean.

For the current week, the company shares have a recommendation consensus of Buy. Arena Pharmaceuticals (NASDAQ:ARNA): stock was range-bound between the intraday low of $1.62 and the intraday high of $1.79 after having opened at $1.78 on Fridays session. The stock finally closed in the red at $1.78, a loss of -4.60%. The stock remained in the red for the whole trading day. The total traded volume was 6,302,748 shares. The stock failed to cross $1.79 in Fridays trading. The stocks closing price on Thursday was $1.66.

Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors (GPCRs). The Companys drug, BELVIQ (lorcaserin HCl), was approved by the United States Food and Drug Administration for marketing in the United States. In addition to BELVIQ, the Company has other drug candidates and compounds at various stages of research and development. The Company is exploring lorcaserins once-a-day, extended release formulation, as an aid to smoking cessation, in combination with phentermine and other agents for weight management, and for other possible indications. The Companys other drug candidates include ralinepag for vascular diseases, APD334 for autoimmune diseases, APD371 for pain and fibrotic diseases, and temanogrel for thrombotic diseases.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.